SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis

Memo
Gabriel RinnerthalerRichard Greil

Abstract

This article reviews the clinically most relevant presentations at the San Antonio Breast Cancer Symposium (SABCS) 2017 on the topics lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis. In a retrospective analysis of the Women's Health Initiative Observational Study, a reduction in the body mass index (BMI) of at least 5% within 3 years significantly reduced the risk of breast cancer compared to women with a stable weight (HR 0.77; 95% CI 0.78-0.98). In the MONALEESA-7 trial investigating ribociclib or placebo in combination with endocrine therapy as first-line treatment in pre- and perimenopausal women with hormone receptor-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer, a significantly longer progression-free survival was shown for patients treated with ribociclib compared to the placebo group (23.8 vs. 13.0 months; HR 0.55; 95% CI 0.43-0.72; P < 0.001). In a pooled toxicity and efficacy analysis of elderly women treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in combination with an aromatase inhibitor in first-line, toxicities of higher grade were more common in elderly compared to younger patients, despite comparable efficacy. And t...Continue Reading

References

Feb 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rowan T ChlebowskiAnne McTiernan
Aug 20, 2004·The New England Journal of Medicine·Massimo CristofanilliDaniel F Hayes
Sep 6, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Fraser SymmansLajos Pusztai
Jun 9, 2012·The Lancet Oncology·Anthony LucciSavitri Krishnamurthy
May 17, 2014·Journal of the National Cancer Institute·Brigitte RackUNKNOWN SUCCESS Study Group
May 3, 2016·Nature·Serena Nik-ZainalMichael R Stratton
Aug 25, 2016·The New England Journal of Medicine·Béatrice Lauby-SecretanUNKNOWN International Agency for Research on Cancer Handbook Working Group
Nov 3, 2016·The New England Journal of Medicine·Gabriel N HortobagyiJoyce O'Shaughnessy
Nov 9, 2017·The New England Journal of Medicine·Hongchao PanUNKNOWN EBCTCG
Apr 21, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitch DowsettJack Cuzick

❮ Previous
Next ❯

Citations

Jun 11, 2019·Frontiers in Endocrinology·Aradhana RaniJohn Murphy
Aug 20, 2019·World Journal of Clinical Cases·Li-Tong YaoYing-Ying Xu

❮ Previous
Next ❯

Software Mentioned

EndoPredict®

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.